A gut bacteria acid may protect aging arteries from stiffening

As people age, their arteries stiffen and thicken in a process called arteriosclerosis, quietly raising the risk of heart attack, stroke and other cardiovascular disease. A new study points to an unexpected ally in slowing that process: a fatty acid made by gut bacteria. Researchers tracked the molecule, caproic acid, across human blood samples, aging mice and lab-grown vascular cells, and found it consistently declined with age and protected blood vessels when levels stayed high. For anyone already worried that gut health ties into their cardiovascular risk, the findings add a concrete molecular link.

Key Takeaways:

• Caproic acid, a short-chain fatty acid (a fiber-fermentation byproduct) made by gut bacteria, was one of only two circulating fatty acids that dropped significantly with age in both a 127-person human cohort and in mice.
• In mice with drug-induced arteriosclerosis, supplementing caproic acid eased artery stiffening, lowered blood pressure measures, and calmed aging-related stress signals in artery wall cells.
• The protection required a specific receptor called GPR41; blocking it in vascular cells wiped out caproic acid's benefit, showing the effect is not just correlation.
• The human data only show a correlation between caproic acid and vascular aging; the protective, cause-and-effect evidence comes from mice and lab cells, not a human clinical trial.

Gut Bacteria's Caproic Acid Falls With Age in Mice and Humans

Researchers screened a panel of short-chain fatty acids (SCFAs, fatty acids gut bacteria produce by fermenting dietary fiber) in blood from both young and aged mice and from a 127-person human cohort, and found caproic acid (also called hexanoic acid) was one of just two SCFAs, alongside butyric acid (butyrate), that dropped significantly with age in both species. In the full human group, caproic acid levels fell as age rose, and lower caproic acid tracked with higher pulse pressure, a marker of stiffening arteries, in both the human cohort and in mice. The team, led by researchers at Xi'an Jiaotong University and published in the Journal of Cardiovascular Aging, also confirmed that their aged mice showed classic signs of arteriosclerosis: nearly a 3-fold increase in aortic arch pulse wave velocity (PWV, the speed blood pressure waves travel through an artery, a standard stiffness measure) compared with young mice, plus thickened, fibrotic artery walls. The finding fits into a growing body of work on the gut-vascular axis, the web of signaling between gut microbes and blood vessel health.

Why This Matters for Anyone Managing High Blood Pressure or Heart Risk

Arteriosclerosis is the underlying process behind most cardiovascular disease in older adults, and it often shows up first as isolated systolic hypertension, high blood pressure with a normal or low diastolic number, which the study's aged human participants also displayed. For the millions of people already tracking blood pressure, cholesterol or a family history of heart disease, a gut-derived molecule that tracks with vessel stiffness is notable less because it is treatable today and more because it offers a new angle on why some people's arteries age faster than others. Anyone managing hypertension, especially isolated systolic hypertension in later life, is the population this research speaks to most directly, since prior research has already tied gut bacteria-derived short-chain fatty acids to cardiovascular and metabolic disease more broadly.

How Researchers Tested Whether Caproic Acid Actually Protects Arteries

Beyond the correlational human data, the team ran two lines of causal evidence in animals and cells. First, they gave young mice with angiotensin II-induced arteriosclerosis (AngII, a hormone used to trigger high blood pressure and vessel damage in a standard preclinical model) daily injections of sodium caproate, the salt form of caproic acid, for four weeks. Treated mice had lower aortic PWV, lower systolic blood pressure and pulse pressure, less collagen buildup and fewer broken elastic fibers in their artery walls, and reduced levels of three senescence proteins (p53, p21 and p16, markers of cells that have stopped dividing and taken on a damaging, inflammatory state) compared with untreated AngII mice. Second, in mouse vascular smooth muscle cells (MOVAS cells) grown in a dish, silencing the gene for GPR41 (a receptor on cell surfaces that caproic acid binds to) completely erased caproic acid's ability to block AngII-induced senescence, showing the protection runs through that specific receptor rather than being a side effect.

What This Could Mean if You're Watching Your Cardiovascular Health

This is not a signal to start taking caproic acid or a specific supplement. No human trial has tested whether raising caproic acid levels, through diet, fiber intake or any other route, actually slows arterial stiffening in people. What the study does offer is a biomarker candidate: because caproic acid tracked so closely with pulse pressure in the human cohort, it could eventually be combined with standard cardiovascular risk markers to flag who is aging faster. That fits a broader pattern seen in other research, including a clinical study showing gut-derived metabolites can help lower blood pressure in patients with hypertension. The authors also note that diets that increase fermentable fiber intake raise gut production of SCFAs like caproic acid, an area worth watching, though it remains unproven as a way to protect arteries.

Why the Case for Caproic Acid Still Has Real Gaps

The human portion of the study was correlational and cross-sectional (a single snapshot in time from one hospital), which means it cannot show that low caproic acid causes stiffer arteries, only that the two go together. The causal evidence, the part that actually shows cause and effect, comes entirely from mice and a single lab-grown cell line, not from a human clinical trial. The mouse arteriosclerosis experiment used only 5 animals per group, and the entire animal study used only male mice, so whether the protective effect holds in females is untested. The researchers also measured caproic acid only in blood, without directly sampling the gut microbiome or stool metabolites, so they cannot yet confirm gut bacteria are the exclusive source of the circulating caproic acid they measured.

What Comes Next for This Research

The authors are calling for larger, multicenter, prospective human studies, ones that follow the same people over time rather than comparing groups at a single visit, to establish whether low caproic acid actually predicts future arteriosclerosis. They also plan to test the effect in female mice and to pair blood caproic acid measurements with direct gut microbiome and stool metabolite data to confirm which bacteria are producing it. Longer term, the team suggests caproic acid could be added to existing cardiovascular risk panels alongside traditional markers, and that dietary strategies to boost fermentable fiber intake deserve dedicated study as a non-drug way to support the pathway, building on emerging reviews of gut-derived short-chain fatty acids and aging.

Common Questions

What is caproic acid and where does it come from? Caproic acid (also called hexanoic acid) is a short-chain fatty acid produced when gut bacteria, mainly from the Lachnospiraceae and Ruminococcaceae families, ferment fiber and other bacterial byproducts in the colon.

Does this mean I should take a caproic acid or short-chain fatty acid supplement? No. The study never tested a caproic acid supplement in people, and the researchers explicitly call for human trials before any intervention could be considered.

What is arteriosclerosis and why does it get worse with age? Arteriosclerosis is the stiffening and structural remodeling of artery walls that raises the risk of heart attack, stroke and high blood pressure, and it accelerates with age as artery cells accumulate damage and take on an inflammatory, senescent state.

Was any of this tested directly in people? Yes, in a 127-person cohort of young and older adults, but only to look at correlations between blood caproic acid and blood pressure markers; the protective, causal experiments were done in mice and lab-grown cells.

References

1. Yifei Xie, Jinglong Pang, Hao Wu, et al. (2026). Gut microbiota-derived caproic acid attenuates aging-associated arteriosclerosis. The Journal of Cardiovascular Aging. https://doi.org/10.20517/jca.2026.41
2. Dezhi Zhang, Xiaoqing He, Yewei Shi, Xinyue Chen, Kai Yu, Shuang Wang (2025). Gut microbiota regulate atherosclerosis via the gut-vascular axis: a scoping review of mechanisms and therapeutic interventions. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2025.1606309
3. Yingdong Lu, Yang Zhang, Xin Zhao, et al. (2022). Microbiota-derived short-chain fatty acids: Implications for cardiovascular and metabolic disease. Frontiers in Cardiovascular Medicine. https://doi.org/10.3389/fcvm.2022.900381
4. (2023). Gut microbial metabolites lower blood pressure in patients with hypertension. Nature Cardiovascular Research. https://doi.org/10.1038/s44161-022-00204-8
5. Pengpeng Xie, Yaoye Pei, Luyun Xu, Yuanhao Shan, Xiamin Cao (2026). Short-Chain Fatty Acids: Bridging Gut Microbiota and Systemic Aging—Mechanisms, Interventions, and Current Challenges. Metabolites. https://doi.org/10.3390/metabo16070438